- In 2013, Dr. Faveret became one of the first Brazilian
physicians to prescribe medical cannabis, subsequently treating
more than 3,000 patients with various conditions across the
country
- As Medical Director for Zerenia™, Dr. Faveret will lead patient
prescriptions, physician outreach and education, and data-driven
product development for Khiron in Brazil, leveraging relationships and deep
medical cannabis expertise developed throughout 30-year career
- Khiron positioned to expand Zerenia™ clinics in key cities in
Brazil following addition of
Medical Director and first sales in Brazil in early July, leveraging Brazilian
marketing agreements and production, distribution, and clinical
assets in Latin America
- Brazil is Latin America's largest addressable market,
with over 200 million people and the potential to reach
USD$1.4 billion in annual revenues
(Source: New Frontier Data)
TORONTO, July 29, 2021 /CNW/ - Khiron Life Sciences Corp.
("Khiron" or the "Company")
(TSXV:KHRN)(OTCQX:KHRNF)(Frankfurt:A2JMZC), a vertically integrated
medical cannabis leader with core operations in Latin America and Europe, is pleased to announce the addition of
renowned physician, pediatric neurologist and clinical
physiologist, Dr. Eduardo Faveret,
as Medical Director for Zerenia™ Brazil. As the Company expands its global
leadership position, the addition of Dr. Faveret represents a major
milestone toward bringing Khiron's market validated clinic strategy
to larger markets in Latin
America.
Dr. Eduardo Faveret, Medical
Director Zerenia™ Brazil
Dr. Faveret is a prominent
advocate for medical cannabis in Brazil and a leading prescriber in the country
of more than 200 million people. In 2013, Dr. Faveret became one of
the first physicians in Brazil to
prescribe medical cannabis extract to a child, subsequently
treating more than 3,000 patients with conditions such as
Alzheimer's, Parkinson's, MS, cancer, anxiety, depression,
insomnia, Tourette's syndrome, autism, and chronic pain, among
others.
Dr. Faveret boasts a highly distinguished medical and academic
career, as the founder and former medical director of the Epilepsy
Center at the Paulo Niemeyer State Brain Institute in
Rio de Janeiro. He completed
post-graduate studies in Pediatric Neurology (Federal University of
Rio de Janeiro and FIOCRUZ) and
specialized in Clinical Neurophysiology and Epileptology in Bonn
Universität and Bethel Epilepsie Zentrum in Germany.
Management Commentary
Alvaro
Torres, Khiron CEO and Director, commented: "We are thrilled
to welcome Dr. Faveret to our team. With over eight years'
experience helping patients access medical cannabis, Dr. Faveret is
a leading medical cannabis specialist in Brazil who shares our mission of improving
patients' lives through medical cannabis. With the goal of
establishing ourselves as the dominant B2C medical cannabis company
in Latin America and Europe, and having proven our ability to
supply Khiron-branded product to Brazilian patients, we look
forward to working with Dr. Faveret to deliver our proven
vertically integrated strategy in Latin
America's largest market."
About Khiron Life Sciences Corp.
Khiron is a leading
vertically integrated medical cannabis company with core operations
in Latin America and Europe. Leveraging wholly-owned medical health
centres and proprietary telemedicine platforms, Khiron combines a
patient-oriented approach, physician education programs, scientific
expertise, product innovation, and agricultural infrastructure to
drive prescriptions and brand loyalty with patients worldwide. The
Company has a sales presence in Colombia, Peru, Germany, UK, and Brazil and is positioned to commence sales in
Mexico in 2021. The Company is led
by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and
diverse executive team and Board of Directors.
Visit Khiron online at investors.khiron.ca and on Instagram
@khironlife.
Cautionary Notes
Forward-Looking Statements
This press release may contain certain "forward-looking
information" and "forward-looking statements" within the meaning of
applicable securities legislation. All information contained herein
that is not historical in nature may constitute forward-looking
information. Khiron undertakes no obligation to comment on
analyses, expectations or statements made by third-parties in
respect of Khiron, its securities, or financial or operating
results (as applicable). Although Khiron believes that the
expectations reflected in forward-looking statements in this press
release are reasonable, such forward-looking statement has been
based on expectations, factors and assumptions concerning future
events which may prove to be inaccurate and are subject to numerous
risks and uncertainties, certain of which are beyond Khiron's
control, including the risk factors discussed in Khiron's Annual
Information Form which is available on Khiron's SEDAR profile at
www.sedar.com. The forward-looking information contained in this
press release is expressly qualified by this cautionary statement
and is made as of the date hereof. Khiron disclaims any intention
and has no obligation or responsibility, except as required by law,
to update or revise any forward-looking information, whether as a
result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that
term is defined in the policies of the TSXV) accepts responsibility
for the adequacy or accuracy of this press release.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/khiron-welcomes-dr-eduardo-faveret-as-medical-director-for-brazil-301344252.html
SOURCE Khiron Life Sciences Corp.